Clinical Report: FDA Accepts Vamikibart BLA for Uveitic Macular Edema
Overview
The FDA accepted Genentech’s biologics license application for investigational vamikibart, an intravitreal IL-6 inhibitor for uveitic macular edema (UME). At 52 weeks, visual and anatomic improvements were generally maintained in the phase 3 MEERKAT and SANDCAT trials, although the trials differed in their primary endpoint results and week-52 visual responder findings.
Background
UME is associated with noninfectious uveitis, and the article notes that macular edema may persist despite treatment of the underlying uveitis. Corticosteroids are described as a mainstay of treatment, with elevated intraocular pressure and cataract formation among their risks. Vamikibart is a monoclonal antibody designed to inhibit IL-6, a proinflammatory cytokine implicated in UME. Earlier phase 1 DOVETAIL findings provided preliminary safety and efficacy signals that supported evaluation in the phase 3 trials.
Data Highlights
| Trial and outcome | Vamikibart 0.25 mg | Vamikibart 1 mg | Sham |
|---|---|---|---|
| MEERKAT, week 16: ≥15-letter ETDRS gain | 26.1% (P=.0008 vs sham) | 43.2% (P<.0001 vs sham) | 6.3% |
| SANDCAT, week 16: ≥15-letter ETDRS gain | 34.0% (nominal P=.0019 vs sham) | 21.8% (P=.1487 vs sham) | 13.3% |
| MEERKAT, week 52: ≥15-letter ETDRS gain | 28.3% | 21.7% | 6.3% |
| SANDCAT, week 52: ≥15-letter ETDRS gain | 23.4% | 17.3% | 12.0% |
| MEERKAT, week 52: mean CST reduction | 167.1 µm | 174.1 µm | 89.3 µm |
| SANDCAT, week 52: mean CST reduction | 188.1 µm | 192.8 µm | 99.1 µm |
The phase 3 trials enrolled 245 participants in MEERKAT and 256 in SANDCAT. Week-52 responder comparisons in MEERKAT were reported as nominally significant; SANDCAT week-52 comparisons were not nominally significant.
Key Findings
- MEERKAT and SANDCAT were identically designed phase 3 trials in adults with UME associated with noninfectious uveitis; participants were randomized equally to intravitreal vamikibart 0.25 mg, vamikibart 1 mg, or sham.
- The primary endpoint was a gain of at least 15 ETDRS letters at week 16. Both vamikibart doses met statistical significance versus sham in MEERKAT, whereas in SANDCAT the 1-mg comparison was not statistically significant and the 0.25-mg result was nominally significant under the testing hierarchy.
- At week 52, visual acuity and central subfield thickness improvements were generally maintained. The treatment difference in visual acuity narrowed in the SANDCAT 1-mg group by study end.
- Mean CST reductions at week 52 were greater in both vamikibart groups than with sham in each trial, as detailed in the table.
- More than half of sham-treated patients required rescue treatment, compared with approximately 20% of vamikibart-treated patients. Among patients eligible for as-needed dosing, approximately 30% required additional injections, and about 85% of those received one additional injection.
- Through 52 weeks, investigators reported relatively low rates of serious ocular adverse events and intraocular inflammation; no ocular occlusive retinal vasculitis cases or new safety signals during the as-needed phase were reported. The related phase 1 DOVETAIL study reported preliminary safety, tolerability, and visual and anatomic improvement signals.
Clinical Implications
The article reports sustained visual and anatomic findings through 52 weeks, but the differing primary endpoint results between MEERKAT and SANDCAT are relevant when interpreting the phase 3 evidence. Vamikibart remains investigational; the article states that the FDA decision on the application was expected by July 2027.
Conclusion
FDA acceptance of the vamikibart BLA follows phase 3 findings of generally maintained visual and anatomic improvements through one year. The trials’ differing efficacy results and the investigational status of the treatment remain important context.
Related Resources & Content
- Jim Gallagher, Retinal Physician, 2026 — FDA Accepts Vamikibart BLA for Uveitic Macular Edema
- JAMA Ophthalmology, 2026 — Intravitreal Interleukin 6 Inhibitors for Uveitic Macular Edema
- MUV Taskforce, 2026 — Imaging Measures for the Assessment of Disease Activity in Noninfectious Posterior Uveitis
- MDSpire News — Vamikibart Shows Early Safety in Uveitic Macular Edema
- retinal physician — IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial
- Ophthalmology Management — FDA Accepts Outlooks Resubmitted BLA for ONS5010 for Wet AMD
- FDA Accepts Vamikibart BLA for Uveitic Macular Edema
- Intravitreal Interleukin 6 Inhibitors for Uveitic Macular Edema
- Imaging Measures for the Assessment of Disease Activity in Noninfectious Posterior Uveitis
- FDA Accepts Vamikibart BLA for Uveitic Macular Edema | Retinal Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







